Detailed introduction, research and development background and market launch status of pesolimab (spesolimab-sbzo)

Pesolimab (spesolimab-sbzo) is an innovative biologic developed for adults with generalized pustular psoriasis (GPP), a rare and serious skin disease. The skin of GPP patients will suddenly appear with widespread erythema and sterile pustules, accompanied by severe pain, fever and other systemic symptoms, which seriously affects the patients' daily life. The launch of pesolimab has brought new treatment prospects to GPP patients.

The research and development background of pesolimab stems from in-depth research on the pathogenesis of GPP. Scientists have discovered that IL-36 cytokine plays a key role in the pathogenesis of GPP. Pesolimab, as a humanized monoclonal antibody, can specifically bind to the IL-36 receptor, thereby blocking the activation of the IL-36 signaling pathway, reducing inflammatory responses, and improving skin symptoms. This discovery provides a solid theoretical basis for the development of pesolimab.

Pessolizumab has made significant progress in terms of market launch status. In September 2022, pesolimab was first approved for marketing in the United States for the treatment of GPP. Subsequently, in December of the same year, pesolizumab was also approved in mainland China, bringing new treatment options to Chinese GPP patients. In addition, pesolimab has also received breakthrough therapy designation from China, the United States and other countries and regions, which further proves its potential and value in the treatment of GPP.

It is worth mentioning that pesolimab has demonstrated significant efficacy and safety in clinical trials. After receiving treatment, most patients can observe a significant reduction in pustules and skin lesions within a short period of time, and the side effects are relatively minor. This result makes pesolimab attract much attention in clinical application and also lays a solid foundation for its promotion in the market.

In general, as an innovative biologic targetingGPP, pesolimab has a strong research and development background and a good market status, providing new treatment hope for GPP patients. With its widespread clinical application, it is believed that pesolimab will bring good news to more patients.

Reference materials：https://www.drugs.com/spevigo.html